The Federal Medical-Biological Agency (FMBA) of Russia has submitted documentation to the Ministry of Health to obtain permission for the use of its cancer vaccine, «Enteromix». This was announced by FMBA head Veronika Skvortsova in an interview.
«Recently, we informed the Ministry of Health of our readiness to begin clinical trials. Everything is prepared for this – a three-year cycle of preclinical studies confirming the vaccine`s safety has been fully completed,» Skvortsova stated on the sidelines of the St. Petersburg International Economic Forum.
The head of the FMBA added that production sites for creating personalized vaccines are already in place. According to her, the agency`s goal for the near future is to bring oncological diseases under control and make them manageable. However, Skvortsova believes that completely solving the problem of cancer in the foreseeable future will not be possible.
The «Enteromix» vaccine was developed by the National Medical Research Center for Radiology of the Ministry of Health in collaboration with the V. A. Engelhardt Institute of Molecular Biology. The preparation utilizes four non-pathogenic viruses capable of both destroying malignant cells and activating the patient`s anti-tumor immunity. Trials on volunteers began on June 20, involving 48 cancer patients.
